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Abstract
Detection of low frequency single nucleotide polymorphisms (SNPs) has important implications in early screening for tumorgenesis,
genetic disorders and pathogen drug resistance. Nucleic acid arrays are a powerful tool for genome-scale SNP analysis, but
detection of low-frequency SNPs in a mixed population on an array is problematic. We demonstrate a model assay for HIV-1 drug
resistance mutations, wherein ligase discrimination products are collected on a suspension array. In developing this system, we
discovered that signalfrom multiple polymorphismswasobscured by two discrete hybridization artifacts. Specifically: 1) tethering of
unligated probes on the template DNA elicited false signal and 2) unpredictable probe secondary structuresimpaired probe capture
and suppressed legitimate signal from the array. Two sets of oligonucleotides were used to disrupt these structures; one to displace
unligated reporter labels from the bead-bound species and another to occupy sequences which interfered with array hybridization.
This artifact silencing system resulted in a mean 21-fold increased sensitivity for 29 minority variants of 17 codons in our model assay
for mutations most commonly associated with HIV-1 drug resistance. Furthermore, since the artifacts we characterized are not
unique to our system, their specific inhibition might improve the quality of data from solid-state microarrays as well as from the
growing number of multiple analyte suspension arrays relying on sequence-specific nucleic acid target capture.
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Introduction
Assays for single nucleotide polymorphisms (SNPs) are useful for
haplotyping [1], identifying pathogen species [2], and screening for
heritable polymorphisms [3]. While many methods are available for
detecting dominant SNPs, a simplemultiplex platform to detect minority
variants might offer greater information yield and could be used for a
broader scope of applications such as detecting SNPs implicated in
somatic cell carcinogenesis [4] or identifying drug resistance muta-
tions arising from pathogen or cancer chemotherapy [5].
Suspension array platforms, like that available from Luminex
(www.luminexcorp.com), are an attractive means for multiple SNP
detection since they allow rapid identification of multiple species in
parallel. Target molecules are captured on optically identifiable
beads and quantified by a flow fluorimeter, an instrument equiva-
lent to a three-color flow cytometer with dedicated gating for beads
in suspension [6]. This system, equivalent to a solid-state array in
many capacities, can be used to simultaneously detect multiple pro-
teins[7]ornucleicacids[2]via identifiablefluorescentsignatureson
beads with a corresponding affinity label.
For SNP detection in the present study, we use this system to
capture and quantify ligase discrimination reaction (LDR) products.
LDR is the discriminatory step in an oligonucleotide ligation assay
(OLA) and uses a high-fidelity DNA ligase to join two adjacent
oligonucleotide probes on a DNA template at a designated mutation
[8](Figure1A–C).Ligation productsarecaptured viaabead-specific
‘‘tag’’ sequence on the 59-terminus of the up-stream oligonucleotide
(bead capture oligonucleotide; BCOs) and a biotin modification on
the 39-terminus of the downstream oligonucleotide (reporter cap-
ture oligonucleotide; RCO; Figure 1A). BCOs and BCO-RCO
ligation products are collected on beads conjugated to appropriate
‘‘antitag’’sequences(thetagcomplement)andwhich containa dual-
fluorophore mixture (for identification; Figure 1D). Bead-captured
BCO-RCO ligation products are labeled with a streptavidin-R-
phycoerythrin conjugate (the reporter fluorophore), enriching beads
with the reporter in proportion to ligase joining. Finally, each bead
is identified (indicating what SNP is being detected) and evaluated
for reporter fluorophore enrichment (indicating how much of that
SNP was present) in a liquid flow as they pass through the optical
chamber in the flow fluorimeter.
Our efforts to detect minority variant LDRproducts on a suspension
array revealed significant signal and background fluctuations which
prevented accurate calculation of sample SNP content, as shown
previously [9,10]. In this report, we have characterized two discrete
hybridization artifacts which cause signal fluctuations and thereby
confound LDR detection on an array. Specifically: 1) carryover
template DNA elicits false signal by tethering the RCO to the bead-
bound BCO in the absence of ligation and 2) unpredictable BCO
secondary structures interfere with bead binding, suppressing bona-
fide array signal. These observations informed design of competimer
and duplex nucleator oligonucleotides to induce benign DNA
hybrids,disrupting the unwanted structures and significantlyimproving
both signal and background. Used together, duplex nucleator and
competimer oligonucleotides improved detection sensitivity by more
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15476than an order of magnitude and, in some cases, enabled quantification
of previously undetectable sequences, as demonstrated by a model
assay for HIV-1 drug resistance mutations.
Results
A Multiplex Assay for Drug Resistant Mutations in HIV-1 Pol
Five classes of antiretroviral drugs, i.e. protease inhibitors (PIs),
nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), integrase
inhibitors (INIs) and entry inhibitors, are commonly prescribed as
part of highly active antiretroviral treatment regimen, but discrete
mutations conferring resistance are observed for only the PI,
NRTI, NNRTI, and INI drug classes. For this study, seventeen
primary HIV-1 drug resistance-associated mutations were chosen
based on definitive phenotypic resistance profiles in HIV-1
subtype B infections [11] (hivdb.stanford.edu, accessed in April
2008; Figure 2A). In oligonucleotide probe design, each BCO was
amended with a 59-terminal ‘‘tag’’, an HIV-unrelated 24-nt DNA
sequence which is complementary to one of the bead-coupled
oligonucleotides (anti-tags) available from the bead manufacturer
(LUA-#; Table S1).
Initial assay performance was demonstrated using a wild-type
amplicon, including most of the HIV-1 pol gene, comprising
protease (PR), reverse transcriptase (RT) and integrase (IN) coding
sequences, as the template DNA for ligase discrimination. As
summarized in Figure 2, each drug resistance site was probed with
an RCO-BCO set (typically one BCO for the mutant sequence,
one BCO for the wild-type sequence and an RCO which can be
ligated to either the mutant or wild-type BCO). The template
DNA was diluted in series, combined with all assay probes (35
BCOs and 20 RCOs) and subjected to ligase discrimination. After
LDRs were complete, suspension array beads (one region for each
of the 35 BCOs), and then a fluorescent reporter (Streptavidin – R-
phycoerythrin), are added to all wells. Subsequent flow fluorimetry
assesses reporter enrichment for each bead region and, since the
reporter fluorophore should only associate with beads via RCO
linkage to the BCO, reporter associated with a specific bead region
reflects how much of the region-associated SNP was present in the
template DNA. The multiplex OLA gave high median fluorescent
intensity (MFI .10,000) for the majority of sites except for RCO-
BCOwtIN-151 (,1000 MFI) and BCO-RCOwt combinations for
protease codons 30, 54, and 84 (,3000 MFI; Figure 2B).
Incorrect probe signal amplitudes were more varied (Figure 2C).
RCO-BCO combinations for RT codons 65, 151, 188 and 190
had the lowest incorrect signals (less than 300 MFI compared to a
mean incorrect signal of 1031 MFI) whereas those for PR codon
82 and RT codons 74, 75 and 103 exhibited the highest incorrect
signals in the dataset (.1000 MFI). These background signals
were unexpected based on previous results with a radioactive
protocol yielding significantly lower background [12].
Characterization of Template-Tethering
To rule out ligase error as the source of high incorrect signal, we
used an 839 bp amplicon (RTS2-RTA8) from HIV-1 reference
plasmid pNL4.3 which includes the wild-type reverse transcriptase
codon 215 ACC. Ligase discrimination reactions and a mock
reaction series (no thermal cycling) were assembled with increasing
amounts of template DNA (0.01 to 10 nanograms per reaction)
with wild-type RCO+BCOwt RT-Thr215 ACC and mutant RCO+
BCOmut RT-Tyr215 TAC probes (Figure 3B–E). As expected, the
correct signal rose sharply in proportion to template input with
thermal cycling (Figure 3C, blue trace). However, the incorrect
signal increased to the same extent with or without thermal cycling
(Figure 3B–C, orange trace). Ultimately, nearly 1000 MFI of
incorrect signal was generated by 10 ng template DNA with and
without enzymatic activity, indicating that the majority of non-
specificsignalwas ligase-independent,i.e.not causedbyligaseerror.
Competimer Oligonucleotides Inhibit Template
Tethering
Carryover template DNA might interact with the RCO and/or
BCO during bead hybridization. If the template DNA interacts
with both the BCO and RCO, it could provide a link between
Figure 1. Ligase discrimination and bead capture. (A) Depictionofa
50%mixtureofwild-typeandmutanttemplate(only thenegativestrandis
shown) in a ligase discrimination reaction query for the mutant SNP. The
mutant BCO comprises an allele-specific region (black) with a template-
unrelated tag sequence at the 59-end (red). The RCO is complementary to
the mutant template DNA downstream from the SNP of interest and is
conjugated to a 39-biotin. (B) During annealing, a mismatch occurs
betweenthewild-typetemplateandthemutant BCO39-end(left)whereas
the mutant probes are complemented by the template across the probe
junction. (C) A template-dependent DNA ligase joins the mutant probe
paironthemutant DNA,butdoesnotjoinmutantprobesonthewild-type
templateDNA due to the mismatch close to the probe junction. (D) Ligase
discrimination products are hybridized to Luminex beads coupled to anti-
tag sequences. Biotin residues on bead-bound RCOs capture a streptavi-
din-R-phycoerythrin reporter. Detection of bead-associated reporter then
reflects the fraction of mutant template in the sample.
doi:10.1371/journal.pone.0015476.g001
Artifact Silencing on an Array
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ligation (Figure 3A, top). To test this hypothesis, a sense-stranded
oligonucleotide was designed with the same sequence as the RCO,
but lacking both a 59-phosphate and 39-biotin (‘‘competimer’’;
Table S3; Figure 3A, bottom). The competimer oligonucleotide
eliminated template-dependent incorrect signal from all reactions
regardless of cycling conditions (Figure 3D–E), consistent with a
model in which template DNA can tether the RCO to bead-bound
BCOs in the absence of ligation (Figure 3A). Furthermore, the
correct signal from a 0.01 ng control input was insignificant
Figure 2. Prototype assay for 17 drug resistance mutations in HIV-1 Pol. (A) Schematic representation of HIV-1 pol gene and relative
locations of drug resistance-associated codons in HIV-1 protease (PR), reverse transcriptase (RT) and integrase (IN) coding regions. (B) Correct signal
from the prototype assay are shown with amplitude in units of median fluorescence intensity (MFI; calculated for $75 beads per well; +/2s.d., N=3
independent experiments). (C) Incorrect signal amplitude in the prototype assay (+/2s.d., N=3 independent experiments). *Multiple incorrect signals
were averaged for PR-084 and IN-148 detections.
doi:10.1371/journal.pone.0015476.g002
Artifact Silencing on an Array
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15476Figure 3. Template tethering. (A) Illustration of competimer oligonucleotide function. Unligated RCOs are tethered to an unligated BCO via the
template DNA during bead hybridization (top). A competimer oligonucleotide displaces the RCO from the bead-bound species. (B–E) Demonstration of
template tethering and effects of a competimer oligonucleotide (all +/2s.d., N=4 independent experiments). Template DNA (2 ng/ml) was diluted with
l-phage DNA at the same concentration. Ligase discrimination reactions were assembled and subjected to 300 thermal cycles or no thermal cycling
(mock). Grey fill indicates the 95% CI calculated from the incorrect signal. (B) Mock series demonstrates false signal in the absence of ligase activity. (C)
Reactions subjectedtothermalcyclingdemonstratesSNP discrimination(blue) andincorrectsignalsimilartopanelB(orange).(D)Mockseriessubjected
to bead hybridization with 25 nM competimer demonstrates false signal suppression. (E) Reactions subjected to thermal cycling and bead hybridization
with 25 nM competimer lack the false signal (orange) shown in panel C. Data for 0.1 ng template input were not significantly different than the same
data point in panel C (open blue square in both panels; MWW p=0.47).
doi:10.1371/journal.pone.0015476.g003
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whereas competimer supplementation extricated this data point
(p=0.03; Mann-Whitney; Figure 3E). Thus, formation of an
alternative hybrid between the competimer and the template DNA
during bead hybridization displaced unligated RCOs from the
bead-bound species and resulted in an estimated 10-fold increased
sensitivity.
Predicted BCO Secondary Structures
We next examined the disparity among correct signals from
the prototype assay. A subset of BCOs with a range of reactivities
(Figure 2B) were analyzed for secondary structure (Figure S2) using
a standard algorithm [13].Results implicated secondary structureas
a possible cause of low signal with BCO, but we suspected that
predictions were inaccurate since they did not account for TMAC
used inhybridizations(2.5 Mfinal)ordeoxyinosineanddeoxyuracil
substitutions in our BCOs, so BCO-bead binding affinities were
measured in-vitro.
BCO sequences corresponding to BCOwtPR 30, BCOwtRT 74,
BCOwtIN 155 and BCOwtRT 188 were modified with a 39-biotin
(BCO mimics; Figure 4A, top) to elicit suspension array signal
without prior LDR and allow functional assessment of bead
binding. Bindingparameters for eachBCO mimic was compared to
that of its 39-biotinylated tag (i.e. a BCO mimic lacking the allele-
specific sequence; Figure 4A, bottom). Since biotinylated tag/BCO
mimic pairs differ only by the presence of the allele-specific
sequence (present in the BCO mimic, absent in the biotinylated tag;
Figure 4A), differential binding can be directly attributed to the
BCO allele-specific sequence.
BCO mimic bead dissociations constants (Kd) and maximal
binding capacities (Bmax) were compared to those of their
biotinylated tag sequences (Figure 4B, ‘‘tag-b’’), wherein the
BCOwt RT 74 mimic served as a reference for high-level correct
signal in the prototype assay and BCOwt PR 30,B C O wt RT 188,a n d
BCOwt IN 155 as referencesfor weaksignals (Figure 2B).Interestingly,
BCOwt RT 74 mimic bead binding was the least efficient in the BCO
mimic subset. In all cases, tag-b sequences bound beads more
efficiently (.3-fold) than BCO mimics containing an identical
sequence (Kd=162pMforBCO wt RT 74 mimic versus 8.9 pM for
the comparable tag-b). Binding maxima followed a similar trend:
that for the BCOwt PR 30 mimic was similar to its tag-b sequence and
other BCO mimics were impaired (Figure 4B). BCO mimic binding
profiles partially explained BCO reactivity in the prototype assay,
but close correlation was not expected since BCO mimic signal is
independent of LDR probe reactivity. Regardless, these data
demonstrate that BCO allele-specific sequences interfere with tag-
antitag recognition, indicating minor variant detection with the
multiplex OLA was hampered by impaired BCO binding and assay
variability was due in part to variability in BCO binding
(BCO mimic Bmax coefficient of variation =0.33 for the data set).
Duplex Nucleators Improve BCO Mimic Binding
To mitigate the negative effects of BCO secondary structures on
bead binding, duplex nucleator oligonucleotides were designed
Figure 4. BCO mimic and tag binding parameters. (A) Illustration of reagents used for the BCO binding assay. Bead-conjugated antitag
sequences (green) bind tag sequences (black) during normal bead hybridization. BCO mimics (top) are identical to the corresponding BCO (allele-
specific sequence in red), but have 39-biotin modifications to elicit suspension array signal without the need for ligation. Biotinylated tag sequences
(tag-b; bottom) are simply BCO mimics lacking the allele-specific sequence. (B) BCO mimic (top) and tag-b (bottom) dissociation constant (Kd) and
maximal binding capacity (Bmax) values (+/2s.d. in parentheses, N=4 independent experiments). (C) Secondary structures in BCO mimics (top)
preclude tag-antitag binding. Duplex nucleator oligonucleotides (DNO; blue; bottom) form a duplex with the BCO allele-specific region, liberating the
tag sequence to bind the bead-bound antitag. (D) DNOs were titrated into bead hybridizations containing 0.42 nM each BCO mimic or biotinylated
oligonucleotide and detected by flow fluorimetry. (E and F) The experiment in panel B was repeated with and without 2.5 nM DNOs to determine
their effects on BCO mimic binding binding as measured by Kd (E) and Bmax (F) values (all +/2s.d., N=4 independent experiments).
doi:10.1371/journal.pone.0015476.g004
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sequence of each BCO. In each case, inclusion of DNOs in the
bead hybridization step increased signal from BCO mimics,
ranging from a slight (Figure 4D; BCOwt RT 30 mimic) to near 3-
fold (BCOwt RT 188 mimic).
BCO mimic binding was assessed in the presence of 25 nM
each DNO (Figure 4E & F). DNOs decreased BCO mimic Kd
values from 1.2-fold (Figure 4E; BCOwt RT 30 mimic), to 2-fold
(BCOwt RT 74 mimic). Of greater consequence, DNOs increased
Bmax values for all BCO mimics to greater than 21,000 MFI
(Figure 4F). For example, BCOwt RT 74 mimic had the lowest Bmax
of all tested, but DNO supplementation increased this value by 2-
fold, normalizing to DNO-supplemented values for other BCO
mimics (overall CV=0.074). Overall, we observed that DNO
supplementation improved BCO binding, consistent with a model
in which efficient tag/anti-tag recognition is precluded by
secondary structure in the BCO (Figure 4C), as well as with
recent studies demonstrating oligonucleotide binding cooperativity
between two oligonucleotides binding to adjacent sites on a single-
stranded DNA [14].
Improved Prototype OLA Performance
In light of improved BCO-bead binding with DNOs, multiplex
OLA performance was evaluated using DNOs in conjunction with
competimers. Duplex nucleator and competimer oligonucleotides
were designed to anneal to the allele-specific portion of each BCO
(compare Figure S1 to Figure 4C) for all remaining sites in the
prototype assay (Table S3 & S4). Rigorous assay characterization
also required a standard control template. Since the HIV-1 sub-
type B pol consensus sequence differs from those of common
laboratory adapted strains, we adapted an oligonucleotide assembly
procedure [15] (Figure S3) to produce clinically-relevant templates
(Table S7). Control sequences, comprising all BCO and RCO
binding sequences in the consensus subtype B HIV-1 pol, were
constructed by ligating 10 short (,100 nt) oligonucleotides (Table
S6) with degenerate positions corresponding to the mutations of
interest (Figure 3A). The single-stranded ligation product was then
PCR amplified and cloned to produce six variants, differing only in
nucleotides corresponding to drug resistance-associated codons
(Table S7). Because drug-resistant HIV-1 variants often exist as
minor components of an otherwise drug-susceptible HIV-1 patient
infection, PCR amplicons from these constructs were paired and
mixed in different proportions (a ‘‘solute’’ template was diluted by a
‘‘solvent’’ template) for analysis by multiplex OLA.
LDRs were detected in the presence or absence of 320 nM each
competimer and 25 nM each duplex nucleator oligonucleotide
(bothaddedinbead hybridization)and analyzed byflowfluorimetry
(Figure S4). Assay sensitivity values for those codons unique to the
solute template were determined by fitting 4-parameter logistic
curves to the corresponding assay signal and calculating the solute
content required to elicit the cutoff value (95% CI calculated from
the solvent template alone; Figure 5).
In the absence of competimer and duplex nucleator oligonucle-
otides (unsupplemented), the log-average sensitivity of this multi-
plex OLA system was 5.1% SNP content. Assay sensitivity was
Figure 5. Duplex nucleator and competimer oligonucleotides
improve assay sensitivity. Abridged consensus subtype B HIV-1 Pol
sequences containing all OLA probe binding sites were produced by
ligase-mediated oligonucleotide assembly (Materials and Methods;
Figure S3). Amplicons from these constructs differed only in the
nucleotides corresponding to the drug resistance-associated codons.
Each synthetic amplicon (solute) was diluted in series with another at
the same concentration (solvent), used as templates in an ligase
discrimination reaction and then subjected to bead hybridization
(unsupplemented) or that with 25 nM competimer and 2.5 nM duplex
nucleator oligonucleotides (supplemented). Assay sensitivity values
reflect the minimal solute template content (%) required to elicit the
cutoff value for the unsupplemented (blue bars) and supplemented
assay (orange bars) (all +/2s.d., N=4 independent experiments).
Codons associated with drug resistance are underlined. Fold sensitivity
improvement values .1 reflect detections where oligonucleotide
supplementation gave a lower sensitivity value (middle column).
Mann-Whitney Rank Sum Test p-values are shown at the right. Assay
sensitivity for (A) seven codon sequences in PR, (B) five codon
sequences in IN and (C) seventeen codon sequences in RT. *Sensitivity
improvements could not be determined for codons PR 54 ATCIle,P R8 8
AATAsn and RT 181 TGTCys because these codons were undetectable in
the unsupplemented assay.
doi:10.1371/journal.pone.0015476.g005
Artifact Silencing on an Array
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BCO+RCO combinations when the competimer and DNO were
included (supplemented) in the bead hybridization step (log-average
sensitivity =0.24% SNP content; overall sensitivity improvement =
21-fold). The greatest improvements were observed in detecting
codons IN 148 CATHis (Figure 5B), RT 151 CAGGly, RT 181
TATTyr,R T7 5G T A Val, RT 184 ATGMet, RT 190 GCAAla and
RT 190 GGAGly (Figure 5C; all .50-fold). The poorest sensitivity
values were observed for codons associated with PR inhibitor
resistance (Figure 5A), despite significant improvements for five (all
p=0.03, 4.5 to 28 fold). Sensitivity values for other RT codons
(Figure 5C) were significantly improved (p#0.05, 2.0 to 195 fold)
for less than 0.5% SNP content, with the exception of 74 TTALeu
and 103 AACAsn. Although assay sensitivity for RT 74 TTALeu
was improved 45-fold, significance for improvement could not be
established (p=0.1) since the unsupplemented assay signal fitted
curves failed validation in two of four experiments (Figure S5).
Assay sensitivity for RT 103 AACAsn was unique in the dataset in
that it was the only codon detection not improved by
oligonucleotide supplementation (p=0.1). Interestingly, wild-type
RT 103 AAALys was the only codon detectable at less than 1% in
a mixture without supplementation (Figure 5C; Table 1).
Discussion
A multiplex OLA for 17 drug resistance-associated mutations in
HIV-1 Pol demonstrated unexpectedly high levels of incorrect
signal on a Luminex suspension array, in contrast to previous
studies showing minimal ligase error when ligation products were
analyzed by denaturing polyacrylamide gel electrophoresis
[12,16]. To reconcile this inconsistency, we investigated the cause
of high incorrect signal and low correct signal for polymorphism
detection using multiplex OLA. Mock reactions analyzed by flow
fluorimetry provided evidence that high incorrect signal was not
ligase-dependent. We proposed that template-dependent incorrect
signals were the result of discrete artifacts created during bead
hybridization wherein template DNA carried over from the
ligation reaction tethered unligated RCOs to unligated BCOs on
the bead. This model was supported by the observation that this
ligase-independent signal was silenced by an oligonucleotide
(competimer) designed to displace the unligated RCO, increasing
assay sensitivity approximately 10-fold.
Oligonucleotide folding thermodynamic calculations indicated
that secondary structures in specific BCO sequences partially
obscured tag residues, so we examined BCO binding quantita-
tively. Binding experiments demonstrated that BCO allele-specific
sequences impaired tag-antitag interaction to a greater extent than
predicted by a standard algorithm for secondary structure. BCO
binding was then rescued by inducing duplex formation in the
BCO allele-specific sequences with an additional oligonucleotide
(duplex nucleator oligonucleotide; DNO), supporting our model
for non-tag sequence interference and, more importantly,
providing an invaluable reagent for the multiplex assay.
Multiplex OLA sensitivity was characterized using template
DNA sequences consisting of an abridged subtype B HIV-1 Pol
gene consensus and six different permutations of drug resistance
mutations. Each amplicon was diluted in series with another at the
same concentration and the resulting mixture was used as a
template for multiplex OLA. Assays supplemented with duplex
nucleator and competimer oligonucleotides gave higher correct
signals and lower incorrect signals than our base protocol, yielding
an average 21-fold gain in assay sensitivity. Moreover, oligonu-
cleotide supplementation produced high signal for three polymor-
phisms which were previously undetectable (Table 1, Figure S5).
As a result, 15 wild type and 14 mutant codons could be accurately
and simultaneously detected at a frequency as low as 0.03%
(average 0.24%).
Fundamental parallels between suspension arrays and solid-state
microarrays suggest a wider application for simplifying unintended
nucleic acid target structures. For example, the Noble group
reported that rigorous thermodynamic calculations could not
account for variations among solid-state microarray probe signals
corresponding to the same rRNA target molecule [17]. In our
system, we improved target binding (the BCO mimic is the target
in this case) to an immobilized probe (the antitag) by occupying an
adjacent site on the target with a third oligonucleotide. It might
then be possible to normalize solid-state RNA (and DNA)
microarray signals for the same target by inducing duplex
formation in target sequences adjacent to the probe binding site
using a similar strategy. Moreover, DNOs and competimers may
also improve and expand the utility of ‘‘next-generation’’ array
systems using holographic bar-coded (Illumina), fluorescence-
encoded (Parallume, Luminex) or high-efficiency scattering
(Nanosphere) particles in suspension.
The current limits of array-based SNP analysis was demon-
strated by a recent study using a similar method (without artifact
silencing) and rigorous background modeling to account for
template-dependent background [10]. After data transformation,
the authors found that a minority variant must comprise 10% of
the sample to attain a call rate of 67%. Thus, the improvements
described herein provide 40-fold greater sensitivity (0.25% mutant
content) than mathematical deconvolution and allow this assay
platform to be used for entirely new methodologies, such as those
for detection of acquired oncogenic polymorphisms and RNA
splice variants as well as pathogen mutations associated with drug
resistance or adverse clinical outcomes. As they relate to our model
system, several studies now suggest that initial presence of minority
drug-resistant HIV-1 variants can predict their eventual domi-
nance and subsequent ARV drug failure [18,19]. Minority drug-
resistant HIV-1 variants may also act as latent reservoirs for
therapeutic inefficacy, since they often persist in patients after
treatment interruption or ARV drug regimen change [19,20].
Thus, early detection of low frequency drug resistance mutations
using multiplex OLA may prolong drug utility and deter HIV-1
disease progression. Toward this end, 17 of the most common
HIV-1 mutations (associated with resistance to NNRTIs, NRTIs,
PIs, and INIs) may be rapidly and simultaneously detected at
frequencies indicative of unfavorable treatment and disease
outcomes. More broadly, the rationale we used to characterize
and resolve suspension array artifacts may provide a means for
others to obtain more accurate and higher quality information
from nucleic acid arrays.
Table 1. Assay performance is improved by oligonucleotide
supplementation.
Sensitivity Bin* Number of Codons
Unsupplemented Supplemented
Undetectable 30
10,S#100 81
1,S#10 17 6
0.1,S#1 11 3
0.01,S#0.1 09
*lowest detectable content
doi:10.1371/journal.pone.0015476.t001
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Oligonucleotide Design
One hundred seventy-four subtype B HIV-1 Pol coding
sequences were obtained from Los Alamos HIV database (www.
hiv.lanl.gov) in April 2008. Oligonucleotide probes were designed
to anneal at 75uC under LDR conditions (40 mM Na
+ and
7.5 mM Mg
2+) and 59-amended with one of 100 tag sequences
(Luminex Corp, Austin, TX). Reference alignment polymor-
phisms occurring with $10% frequency were accommodated with
non-standard bases (deoxyuridine to accommodate frequent purine
transitions or transversions in the negative strand; deoxyinosine to
accommodate frequent pyrimidine transitions) in the probe
sequences, as previously reported [16]. Probe codon specificities
correspondedtomutationsmostfrequentlyobservedinthe Stanford
HIV Drug Resistance Database (hivdb.stanford.edu, accessed April
2008; Figure 2A). Secondary structure thermodynamics were
predicted using the DINA Melt Two-State Folding interface [13]
in 10 mM Na
+ and 1.5 mM Mg
2+. BCOs are shown in Table S1,
RCOs in Table S2, competimer oligonucleotides in Table S3, and
duplex nucleator oligonucleotides (DNOs) in Table S4.
Positive Control Templates
Plasmid pNL4.3 was PCR-amplified with either ML-gag-F3 (nt
2047-2081, HXB2 numbering) and ML-int-R2 (nt 4763–4799), or
RTS2 (nt 2691–2715) and RTA8 (nt 3505–3529; Table S5) with
Platinum Taq DNA Polymerase (Invitrogen) at 95uC (2 min.), 35
cycles of 95uC (30 sec.), 55uC (30 sec.), 72uC (1 min.) and final
extension at 72uC (10 min.). Amplicons were purified using the
Qiagen PCR Cleanup Kit, verified by agarose gel electrophoresis,
quantified using the PicoGreen fluorescence assay (Invitrogen) on
a Perkin-Elmer Victor 3 fluorescent plate reader (Perkin-Elmer;
Waltham, MA) and diluted to 2 ng/ml in ultrapure water and
then, for Figures 2 and 3, with l-phage DNA (2 ng/ml).
Control Templates Produced by Ligase-Mediated
Oligonucleotide Assembly
Control DNA sequences for Figures 5 and S4 were produced
similar to that reported previously [15] (details of our adaptation
are shown in Figure S3). The HIV-1 subtype B consensus
sequence was trimmed to OLA probe target regions and divided
into 10 shorter (,100 nt) segments to produce 59-phosphorylated
(assembly) oligonucleotide sequences. Nine additional (junction
span) oligonucleotides were designed to define the order of
assembly oligonucleotide joining (Figure S3A). The resulting 19
oligonucleotides (AP-01 through AP-10 and JS-01 through JS-09;
Table S6) were combined (2.5 nM each) with 5 Units Ampligase
DNA ligase and 1X Ampligase buffer in 50 ml, heated to 95uC and
slowly cooled to 20uC. Five microliters of the assembly reaction
was PCR-amplified using primers LigPol-F2 and LigPol-R2
(200 nM final, Table S5, Figure S3B) with Platinum Taq DNA
Polymerase and 1X Platinum Taq buffer in 50 ml using the PCR
conditions above. PCR products were cloned into pCR2.1-TOPO
and grown in TOP10 cells (Invitrogen). DNA sequences were
verified by DNA sequencing (ACGT, Inc.). Plasmid inserts were
PCR amplified (LigPol-F2 and LigPol-R2; same conditions as
above, Figure S3C), processed as above and diluted to 5 ng/ml.
Ligase Discrimination Reactions (LDRs)
Except where indicated otherwise, ligase discrimination reac-
tions used 10 ng (Figure 2) or 25 ng (Figures 5 and S4) template
DNA, 5 units of Ampligase DNA ligase (Epicentre Biotechnolo-
gies, Madison, WI) in a 12 ml reaction containing 7.5 nM each
oligonucleotide probe, 15 mM Tris-HCl pH 8.3, 0.06% Triton-
X100, 1 mM dithiothreitol, 40 mM KCl, 7.5 mM MgCl2,
0.3 mM nicotinamide adenine dinucleotide sodium salt and
0.08% polyethylene glycol (mean molecular weight ,6000 Da)
and subjected to 150 or 300 cycles (where indicated) of 95uC
(10 sec.) and 37uC (40 sec.).
Bead and Streptavidin-R-Phycoerythrin Hybridization,
Flow Fluorimetry
Approximately 750 of each xTAG bead, competimer and/or
DNO (where indicated) were added to each LDR in 1X TMAC
buffer (2.5 M tetramethylammonium chloride (TMAC), 0.1 M
Tris-HCl (pH 8.0), 3 mM ethylenediaminetetraacetic acid and
0.1% sodium dodecyl sulfate) in 60 ml and subjected to 95uC
(5 min.) and 37uC (45 min.), followed by addition of a Strepta-
vidin-R-phycoerythrin conjugate (100 ng/well; Invitrogen #S-
866) in 6 ml 1X TMAC buffer and incubation at 37uC (45 min.).
Seventy-five beads per region were measured on a Luminex 200
instrument with BioPlex Manager software (Bio-Rad Life Sciences,
Hercules, CA) at the highest reporter channel photomultiplier tube
voltage setting (typically 700–750 V).
Sensitivity Estimation, Curve Fitting and Statistical
Analyses
BCO mimic and tag-b Kd and Bmax values were calculated in
Origin8 (OriginLab Corp,Northampton,MA)using a 4-parameter
logistic equation. For assay sensitivity experiments, cutoff values
were determined by calculating the 95% CI for the signal elicited by
thesolventtemplatealone.Correctsignalamplitudewasmodeled in
Origin 8 as a function of the solute HIV-1 amplicon (given as % of
total input) and by curve fitting (as above). Curve fitting parameters
were used to determine the minimal template DNA input required
to elicit the cutoff value. Statistical analyses were performed using
the Mann-Whitney-Wilcoxon Rank Sum Test implementation in
Minitab 15 (State College, PA) wherein p#0.05 was considered
significant.
Supporting Information
Figure S1 Duplex nucleator oligonucleotides facilitate
bead binding. For analysis of LDR products, duplex nucleator
oligonucleotides bind to the allele-specific region of the ligated
BCO, similar to that shown in Figure 4C. (EPS)
Figure S2 Predicted BCO secondary structures. BCO
sequences were folded using the DINAMelt Server interface
(http://dinamelt.bioinfo.rpi.edu/) in 10 mM Na
+ and 1.5 mM
Mg
2+, corresponding to bead hybridization conditions. Red
outlines indicate tag sequences. (A) BCOwt PR 30 was absent of
predicted secondary structure in the tag region. (B) BCOwt RT 74
was predicted to form a weak hairpin at the 39-end but no
secondary structure in the tag sequence. (C) BCOwt RT 188 formed
a complex secondary structure at the 39-end of the sequence. (D)
BCOwt IN 155 predicted secondary structure involved 8 nt of the
tag sequence. (EPS)
Figure S3 Ligase-mediated oligonucleotide assembly.
The HIV-1 subtype B consensus sequence was constructed from 10
59-phosphorylated ‘‘assembly’’ oligonucleotides (AP#) assembled in
an order defined by nine 39-aminated ‘‘junction span’’ oligonucle-
otides (JS#). Twenty-four degenerate positions corresponding to
codons of interest are depicted by red circles (some mutant codons
differed from the wild-type sequence by two or three nucleotides).
(A) Assembly and junction span oligonucleotides are combined in a
single tube with a thermostable template-dependent DNA ligase.
Magnification shows 59-phosphate and 39-amine modifications on
the assembly and junction span oligonucleotides, respectively. The
Artifact Silencing on an Array
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DNA with the desired sequence. (B) The single stranded ligation
product is PCR amplified from the 59- and 39-ends to produce an
amplicon with the desired sequence and heterogeneity in codons of
interest. (C) The bulk amplicon was cloned (see Materials and
Methods) and verified by DNA sequencing. Six variants were
selected for PCR amplification and for further analysis by multiplex
OLA (Table S7). (EPS)
Figure S4 Oligonucleotide supplementation increases
correct signal, decreases incorrect signal. Abridged
consensus subtype B HIV-1 Pol sequences containing all OLA
probe binding sites were produced by ligase-mediated oligonucle-
otide assembly (Figure S3), cloned and PCR-amplified to produce
amplicons which differed only in the nucleotides corresponding to
the drug resistance-associated codons. Synthetic amplicons (solute)
were diluted in series with another at the same concentration
(solvent), used as LDR templates and subjected to either normal
bead hybridization (unsupplemented) or that with 25 nM
competimer and 2.5 nM duplex nucleator oligonucleotides
(supplemented). Signals from the correct (‘‘100% solute’’) and
incorrect (‘‘100% solvent’’) synthetic templates corresponding to
(A) seven codon sequences in PR, (B) five in IN and (C) seventeen
in RT (all +/2s.d., N=4). (EPS)
Figure S5 RT-74-TTALeu did not produce evaluable
trends in two of four experiments without oligonucleo-
tide supplementation. Data from two unsupplemented
experiments (grey traces) detecting RT-74-TTALeu failed to direct
the curve-fitting routine to convergence. Orange traces depict
unsupplemented experiments for which curve fitting converged.
Blue traces depict signals from four experiments with oligonucle-
otide supplementation. (EPS)
Table S1 Bead capture oligonucleotides. (DOC)
Table S2 Reporter capture oligonucleotides. ‘‘p-’’ and ‘‘-b’’
depict 59-phosphate and 39-biotin modifications, respectively. (DOC)
Table S3 Competimer oligonucleotides. (DOC)
Table S4 Duplex nucleator oligonucleotides. (DOC)
Table S5 PCR Oligonucleotides. (DOC)
Table S6 Assembly and junction span oligonucleotides
for ligase-mediated oligonucleotide assembly. ‘‘p-’’ and
‘‘-amine’’ depict 59-phosphate and 39-amine modifications,
respectively. (DOC)
Table S7 Synthetic HIV-1 subtype B consensus clone
sequences. (DOC)
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